HER-2 Positive Breast Cancer
Conditions
Keywords
her2 positive breast cancer, her2 positive non operable breast cancer, her2 positive locally advanced breast cancer, neoadjuvant trastuzumab, pathologic complete response
Brief summary
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer
Interventions
DRUGTrastuzumab
neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
Sponsors
Lucia Del Mastro,MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Performance StatusEstearn Cooperative Oncology Group (ECOG) 0-1 2. Histologically confirmed invasive breast cancer, 3. Primary tumour greater ≥ 2 cm diameter, measured by clinical examination and mammography or echography or Nuclear Magnetic Resonance (NMR) candidate to neoadjuvant chemotherapy , 4. Any N, 5. No evidence of metastasis (M0); 6. Over expression and/or amplification of HER2 in the invasive component of the primary tumour according to one of the following definitions: 7. 3+ over expression by immunohistochemistry (IHC) (\> 30% of invasive tumour cells), 8. 2+ or 3+ (in 30% o less neoplastic cells) overexpression by IHC and in situ hybridization (FISH/CISH) test demonstrating Her2 gene amplication , 9. Her 2 gene amplication by FISH/CISH (ratio \> 2.2); 10. Known hormone receptor status 11. Hematopoietic status: 1. absolute neutrophil count ≥ 1.5 x 109/L, 2. platelet count ≥ 100 x 109/L, 12. Hepatic status: 1. serum total bilirubin ≤ 1.5 x ULN. In the case of known Gilbert's syndrome a higher serum total bilirubin (\< 2 x ULN) is allowed, 2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN, 3. alkaline phosphatase ≤ 2.5 times ULN; 13. Renal status: a. Creatinine ≤ 2.0 mg/dL; 14. Cardiovascular: a. baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by echocardiography or multigate acquisition scan (MUGA); 15. For women of childbearing potential negative serum pregnancy test 16. Written informed consent.
Exclusion criteria
1. Male gender 2. Pregnant or lactating women 3. Received any prior treatment for primary invasive breast cancer 4. Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (\> 180/110), unstable diabetes mellitus, dyspnoea at rest or chronic therapy with oxygen; 5. Active or uncontrolled infection, 6. Dementia altered mental status or any psychiatric condition that would prevent the under standing or rendering of informed consent, 7. Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies), 8. Previous or concomitant malignancy within the past 3 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. 9. Concurrent disease or condition that would have make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologic complete response | at definitive surgery within 4 weeks after the last dose of paclitaxel and concurrent trastuzumab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiotoxicity | one year | — |
| disease free survival | one year | — |
| safety and tolerability | one year | safety and tolerability will be assessed by standard clinical and laboratory tests (hematology, serum chemistry). Toxicity grade is defined by the NCI Common Toxicity Criteria (CTC) Adverse Event (AE) v 3.0 |
| rate of conversion from radical to conservative surgery | definitive surgery | — |
| potential biomarkers of trastuzumab resistance | one year | — |
| overall survival | one year | — |
Countries
Italy
Outcome results
None listed